Evidence mapPaperPMID 41563442Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026

Longitudinal biomarker trajectories and their prognostic utility for 21-day mortality in burn patients with sepsis: a retrospective cohort study.

Jiaqi Lou, Hong Kong, Jiliang Li, Ziyi Xiang, Xiaoyu Zhu, Shengyong Cui, Neng Huang, Sida Xu, Guoying Jin, Xin Le and 1 more

Abstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Dynamic risk stratification in burn sepsis: methodological considerations and path forward.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiaqi Lou *Burn Department, Ningbo No. 2 Hospital, No. 41 Northwest Street, Haishu District, Ningbo, 315010, Zhejiang Province, China.
Hong Kong *Ningbo College of Health Sciences, Ningbo, Zhejiang Province, China.
Jiliang Li *Burn Department, Ningbo No. 2 Hospital, No. 41 Northwest Street, Haishu District, Ningbo, 315010, Zhejiang Province, China.
Ziyi Xiang *Institute of Pathology, Faculty of Medicine, University of Bonn, 53127, Bonn, Germany.
Xiaoyu ZhuHealth Science Center, Ningbo University, Ningbo, Zhejiang, China.
Shengyong CuiBurn Department, Ningbo No. 2 Hospital, No. 41 Northwest Street, Haishu District, Ningbo, 315010, Zhejiang Province, China.
Neng HuangBurn Department, Ningbo No. 2 Hospital, No. 41 Northwest Street, Haishu District, Ningbo, 315010, Zhejiang Province, China.
Sida XuBurn Department, Ningbo No. 2 Hospital, No. 41 Northwest Street, Haishu District, Ningbo, 315010, Zhejiang Province, China.
Guoying JinBurn Department, Ningbo No. 2 Hospital, No. 41 Northwest Street, Haishu District, Ningbo, 315010, Zhejiang Province, China. guoyingking@163.com.
Xin LeBurn Department, Ningbo No. 2 Hospital, No. 41 Northwest Street, Haishu District, Ningbo, 315010, Zhejiang Province, China. 13094991@qq.com.
Youfen FanBurn Department, Ningbo No. 2 Hospital, No. 41 Northwest Street, Haishu District, Ningbo, 315010, Zhejiang Province, China. 13906683613@163.com.

Funding

HwaMei Research Foundation of Ningbo No.2 Hospital No.2022HMKY48 and No.2023HMZD07Medical Scientific Research Foundation of Zhejiang Province No.2021KY1004, No.2023RC081 and No.2025KY1395Ningbo Health Youth Technical Backbone Talent Development Program 2024RC-QN-02Ningbo Top Medical and Health Research Program 2023030615Project of NINGBO Leading Medical & Health Discipline 2022-F17Zhejiang Clinovation Pride CXTD202502004Zhu Xiu Shan Talent Project of Ningbo No.2 Hospital 2023HMYQ25
6 · The paper itself

Abstract

objectiveTo characterize the longitudinal trajectories of multi-category biomarkers and evaluate their association with 21-day all-cause mortality in critically ill burn patients with sepsis.

methodsIn this retrospective single-center cohort study, we analyzed 943 adult burn patients with sepsis, defined per Sepsis-3.0 criteria. Serial measurements of 15 biomarkers across nutritional, immunoglobulin, lymphocyte subset, inflammatory, and other categories were collected over 21 days. We employed linear mixed-effects models (LME) to compare trajectories between survivors and non-survivors, Cox regression to assess associations with mortality, time-dependent ROC to evaluate predictive performance, and k-means clustering to identify patient phenotypes based on integrated ALB, IL-6, and IgG trajectories.

resultsThe 21-day mortality was 17.92%. LME revealed significantly different trajectories for 11 biomarkers between survivors and non-survivors (P < 0.05). Univariate Cox analysis identified multiple significant biomarkers, with transferrin (HR = 0.985, P = 6.84 × 10⁻

conclusionsThe dynamic patterns of multi-category biomarkers are strongly associated with short-term survival in burn sepsis. While burn severity is a dominant baseline risk factor, longitudinal trajectory analysis captures the essence of the host's recovery or failure, effectively stratifying patients into prognostically distinct subgroups. This trajectory-based phenotyping highlights the potential of monitoring the host response over time to improve risk assessment and guide personalized management.

Indexed as

BurnsSepsisAdultAgedBiomarkersFemaleHumansLongitudinal StudiesMaleMiddle AgedPrognosisRetrospective StudiesBiomarkersBurn sepsisIntensive Care UnitLongitudinal trajectoriesMulti-category biomarkersPrognosisSurvival prediction

Identifiers

PMID41563442
PMCPMC12823687

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.